Bio-Rad Laboratories Inc - Class A (BIO) Valuation

Based on the provided data, Bio-Rad Laboratories trades at a significant discount to the GoodMoat Target of $938.27. At the current price of $273.6, this implies a margin of safety of approximately 71%. According to the GoodMoat Investment Framework's valuation bands, a margin of safety greater than 40% is considered 'Deeply Undervalued,' placing BIO firmly in that category. The stock's P/E of 9.7x is also extremely low, especially for a healthcare company with a 29.4% profit margin, suggesting the market prices it as a stagnant or troubled business rather than a quality compounder. This stark valuation disconnect is the central point of analysis. A value investor must now investigate whether this deep undervaluation is a market inefficiency or a rational reflection of underlying business risks, such as the low 1.8% operating margin or modest 3.9% revenue growth. The framework dictates that such an attractive price only becomes a favourable opportunity if the company first passes the 'Moat & Quality Gate' with a strong underlying business. The low P/E and high margin of safety create a compelling starting point for deeper due diligence into the company's competitive advantages and financial health. Analysis based on data as of 2024-05-15.